MOUNJARO® 10mg KwikPen®, 1 Stk.

Description

Name: MOUNJARO® 10mg KwikPen®, 1 Stk.
Manufacturer: Eli Lilly and Company Limited
Active Substance(s): TIRZEPATIDE
Strength: 10mg/0.6ml injection
Package Content: 1 box with 4 pre-filled KwikPens

MOUNJARO® 10mg KwikPen® is a multi-dose pre-filled injection pen designed to deliver 10 mg tirzepatide in 0.6 mL once weekly. It is prescribed for adults with type 2 diabetes mellitus who require better glycaemic control and for weight management in patients with obesity or overweight accompanied by health-related conditions. Each KwikPen® contains 2.4 mL of solution, which corresponds to 40 mg tirzepatide in total, and provides four fixed weekly doses. The solution is clear, colourless to slightly yellow, and administered by subcutaneous injection into the abdomen, thigh, or upper arm.

• Provides 4 fixed doses of 10 mg (0.6 mL per injection)

• Once-weekly injection designed for convenience and adherence

• Used as a maintenance strength in ongoing therapy

The device is supplied as a KwikPen® pre-filled with 2.4 mL of solution for four injections. Packs are available in cartons with either one or three pens. Pen needles are not included and need to be purchased separately.

The formulation consists of tirzepatide as the active ingredient, supported by excipients that maintain stability and sterility.

• Active substance: Tirzepatide 10 mg per 0.6 mL injection

• Total pen content: 40 mg tirzepatide in 2.4 mL (16.7 mg/mL concentration)

• Excipients: Disodium hydrogen phosphate heptahydrate, benzyl alcohol (~5.4 mg per dose), glycerol, phenol, sodium chloride, sodium hydroxide, hydrochloric acid, and water for injections

• Sodium content: Less than 1 mmol (23 mg) sodium per dose, essentially sodium-free

• Appearance: Clear, colourless to slightly yellow solution

MOUNJARO® 10mg KwikPen® is indicated for adults with type 2 diabetes mellitus as monotherapy when metformin is unsuitable, or in combination with other antidiabetic medicines. It is also approved for weight management in adults with BMI ≥30 kg/m², and in those with BMI ≥27 kg/m² who also present with at least one weight-related comorbidity, such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or prediabetes.

• Indications:

  • Management of type 2 diabetes mellitus

  • Weight loss and maintenance in patients with BMI ≥30 kg/m²

  • Weight control in overweight adults (BMI ≥27 kg/m²) with comorbidities

• Contraindications:

  • Hypersensitivity to tirzepatide or formulation excipients

  • Not recommended in patients with severe gastrointestinal disorders (e.g., gastroparesis)

  • Use with caution in patients with prior pancreatitis

• Side effects:

  • Very common: Nausea, vomiting, diarrhoea, constipation, abdominal pain

  • Common: Loss of appetite, dyspepsia, dizziness, fatigue, mild injection-site reactions

  • Occasional: Gallbladder-related disorders such as gallstones or cholecystitis

  • Rare: Acute pancreatitis, severe hypersensitivity reactions (angioedema, anaphylaxis)

  • Laboratory findings: Increases in amylase and lipase

MOUNJARO® 10mg is injected once weekly, at the same time each week, with or without food. It is administered into the abdomen, thigh, or upper arm, and injection sites should be rotated to reduce irritation. Patients may self-inject after receiving appropriate training.

• Dosing protocol:

  • Initiation begins at 2.5 mg weekly for 4 weeks

  • Gradually escalate in 2.5 mg increments every ≥4 weeks

  • 10 mg serves as a maintenance dose for many patients

  • Maximum weekly dose: 15 mg

• Missed dose instructions:

  • If ≤4 days late: administer as soon as possible

  • If >4 days late: skip the missed dose and take the next scheduled dose

• Administration steps:

  • Attach a new sterile needle before each use

  • Dial to 1 in the window (=0.6 mL dose)

  • Inject subcutaneously, hold for 5 seconds until window shows 0

  • Remove and discard the needle in a sharps container

Storage conditions must be followed to preserve product quality and safety.

• Unopened pens: Store refrigerated at 2–8 °C

• Do not freeze; discard if frozen

• In-use pens: Store at ≤30 °C for up to 30 days

• Discard after 30 days, even if solution remains

• Safety: Keep out of reach of children

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.